美国血液技术 2026年季度报告

FORM 10-Q HAEMONETICS CORPORATION Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to besubmitted pursuant to Rule405 of RegulationS-T (§232.405 of this chapter) during the preceding 12months (or for such shorter Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act.) Yes☐NoThe number of shares of $0.01 par value common stock outstanding as of January30, 2026: 46,471,350. PART I. FINANCIAL INFORMATION ITEM 1. Financial Statements Unaudited Condensed Consolidated Statements of Income - Three and Nine Months Ended December27, 2025 andDecember28, 20243Unaudited Condensed Consolidated Statements of Comprehensive Income - Three and Nine Months EndedDecember27, 2025 and December28, 20244 Unaudited Condensed Consolidated Balance Sheet - December27, 2025 and Consolidated Balance Sheet - March29, 2025 ITEM 3. Quantitative and Qualitative Disclosures about Market Risk 52 SIGNATURES HAEMONETICS CORPORATION AND SUBSIDIARIESNOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 1. BASIS OF PRESENTATION Basis of Presentation The accompanying unaudited condensed consolidated financial statements of Haemonetics Corporation (“Haemonetics” or the“Company”) presented herein have been prepared in accordance with generally accepted accounting principles in the United States ofAmerica (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article10 of RegulationS-X.Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In theopinion of the Company’s management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financialstatements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Therewere no material recognized or unrecognized subsequent events as of or for the nine months ended December 27, 2025, except for 2. RECENT ACCOUNTING PRONOUNCEMENTS Recently Issued Accounting Pronouncements Not Yet Adopted In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Codification (“ASC”) UpdateNo. 2023-09,Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASC Update No. 2023-09 requires disaggregatedinformation about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. ASC Update No.2023-09 is effective for the Company’s first fiscal year beginning after December 15, 2024 and early adoption is permitted. ASCUpdate No. 2023-09 is applicable to Haemonetics beginning with the fiscal 2026 Annual Report on Form 10-K. The guidance will be In November 2024, the FASB issued ASC Update No. 2024-03,Income Statement - Reporting Comprehensive Income - ExpenseDisaggregation Disclosures. ASC Update No. 2024-03 requires detailed cost and expense information disaggregated in the financialstatement notes. The updated guidance is effective for fiscal years beginning after December 15, 2026 and interim reporting periodswithin annual reporting periods beginning after December 15, 2027, with early adoption permitted. ASC Update No. 2024-03 is In July 2025, the FASB issued ASC Update No. 2025-05,Financial Instruments - Credit Losses(Topic 326). ASC Update No. 2025-05 introduces a practical expedient related to the estimation of expected credit losses for current accounts receivable and currentcontract assets that arise from transactions accounted for under FASB Accounting Standards Codification 606. Under ASC Update No.2025-05, an entity is required to disclose whether it has elected to use the practical expedient. An entity that makes the accountingpolicy election is required to disclose the date through which subsequent cash collections are evaluated. The updated guidance iseffective for fiscal years beginning December 15, 2025, with early adoption permitted. ASC Update No. 2025-05 is applicable to In September 2025, the FASB issued ASC Update No. 2025-06,Intangibles - Goodwill and Other - Internal-Use Software. ASCUpdate No. 2025-06 eliminates references to development stages in the capitalization guidance and requires costs to be capitalizedonce management authorizes funding a